{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T05:46:14Z","timestamp":1790487974177,"version":"4.1.0"},"reference-count":90,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2006,1,20]],"date-time":"2006-01-20T00:00:00Z","timestamp":1137715200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2006,2]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>Infliximab, the chimeric monoclonal IgG1 antibody to tumour necrosis factor, is indicated for refractory luminal and fistulizing Crohn's disease and extra\u2010intestinal manifestations of inflammatory bowel disease. Recently, the active ulcerative colitis trials (ACT) studies have shown that infliximab is also efficacious to treat ulcerative colitis resistant to standard therapy. Induction with 5\u2003mg\/kg infliximab at weeks 0, 2 and 6 is advocated.<\/jats:p>\n                  <jats:p>The response to infliximab is improved when concomitant immunosuppressive therapy is given. As the majority of patients will relapse if not retreated, a long\u2010term strategy is necessary. Although episodic therapy can be used, the optimal strategy is systematic maintenance treatment with 5\u2003mg\/kg intravenous (i.v.) every 8\u2003weeks. Long\u2010term maintenance therapy with infliximab results in a reduction of the rate of complications, hospitalizations and surgeries associated with Crohn's disease.<\/jats:p>\n                  <jats:p>Safety problems with the monoclonal antibody infliximab treatment mainly concern the formation of antibodies to infliximab, which may lead to infusion reactions, loss of response and serum sickness\u2010like delayed infusion reactions. Latent tuberculosis needs to be screened for. The rate of other opportunistic infections is slightly increased mainly in patients treated concomitantly with immunosuppression. There is no evidence that malignancy rates in patients treated with antitumour necrosis factor strategies are increased.<\/jats:p>","DOI":"10.1111\/j.1365-2036.2006.02786.x","type":"journal-article","created":{"date-parts":[[2006,1,20]],"date-time":"2006-01-20T10:45:55Z","timestamp":1137753955000},"page":"451-463","source":"Crossref","is-referenced-by-count":181,"title":["Review article: infliximab therapy for inflammatory bowel disease \u2013 seven\u2003years on"],"prefix":"10.1111","volume":"23","author":[{"given":"P.","family":"RUTGEERTS","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"VAN ASSCHE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"VERMEIRE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,1,20]]},"reference":[{"key":"e_1_2_4_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.35.3.360"},{"key":"e_1_2_4_3_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.26279"},{"key":"e_1_2_4_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.39.1.82"},{"key":"e_1_2_4_5_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365529509096316"},{"key":"e_1_2_4_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(98)70420-2"},{"key":"e_1_2_4_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198005013021801"},{"key":"e_1_2_4_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.37.5.674"},{"key":"e_1_2_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)90402-X"},{"key":"e_1_2_4_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199502023320503"},{"key":"e_1_2_4_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200006013422202"},{"key":"e_1_2_4_12_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2004.045294"},{"key":"e_1_2_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(94)90398-0"},{"key":"e_1_2_4_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.1993.tb05997.x"},{"key":"e_1_2_4_15_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.46.8.757"},{"key":"e_1_2_4_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2002.07029.x"},{"key":"e_1_2_4_17_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2001.00956.x"},{"key":"e_1_2_4_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(99)70224-6"},{"key":"e_1_2_4_19_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.28702"},{"key":"e_1_2_4_20_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.50.2.206"},{"key":"e_1_2_4_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(03)00382-2"},{"key":"e_1_2_4_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(03)80497-3"},{"key":"e_1_2_4_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2005.02309.x"},{"key":"e_1_2_4_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2005.01.007"},{"key":"e_1_2_4_25_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.24042"},{"key":"e_1_2_4_26_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.28674"},{"key":"e_1_2_4_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199710093371502"},{"key":"e_1_2_4_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08512-4"},{"key":"e_1_2_4_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(99)70332-X"},{"key":"e_1_2_4_30_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2003.11.014"},{"key":"e_1_2_4_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199905063401804"},{"key":"e_1_2_4_32_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030815"},{"key":"e_1_2_4_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-3565(04)00414-8"},{"key":"e_1_2_4_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9270(02)05909-9"},{"key":"e_1_2_4_35_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01427.x"},{"key":"e_1_2_4_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10350-004-6111-6"},{"key":"e_1_2_4_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2001.03612.x"},{"key":"e_1_2_4_38_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1445-5994.2001.00039.x"},{"key":"e_1_2_4_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.3780070505"},{"key":"e_1_2_4_40_2","doi-asserted-by":"publisher","DOI":"10.1097\/00054725-200203000-00002"},{"key":"e_1_2_4_41_2","doi-asserted-by":"publisher","DOI":"10.1155\/2002\/379307"},{"key":"e_1_2_4_42_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2002.01268.x"},{"key":"e_1_2_4_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1590-8658(02)80038-X"},{"key":"e_1_2_4_44_2","doi-asserted-by":"publisher","DOI":"10.1080\/gas.37.7.818.824"},{"key":"e_1_2_4_45_2","first-page":"A2691","article-title":"Response to infliximab is decreased in the presence of intestinal strictures in patients with Crohn's disease","volume":"94","author":"Lichtenstein GR","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_4_46_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2002.05991.x"},{"key":"e_1_2_4_47_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.35390"},{"key":"e_1_2_4_48_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01574.x"},{"key":"e_1_2_4_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2005.01.019"},{"key":"e_1_2_4_50_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2003.07343.x"},{"key":"e_1_2_4_51_2","doi-asserted-by":"publisher","DOI":"10.1097\/00054725-200411000-00008"},{"key":"e_1_2_4_52_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005176-200407000-00010"},{"key":"e_1_2_4_53_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005176-200109001-00007"},{"key":"e_1_2_4_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2003.12.014"},{"key":"e_1_2_4_55_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10350-004-6611-4"},{"key":"e_1_2_4_56_2","doi-asserted-by":"publisher","DOI":"10.1097\/00054725-200105000-00001"},{"key":"e_1_2_4_57_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.52.7.998"},{"key":"e_1_2_4_58_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-200411000-00014"},{"key":"e_1_2_4_59_2","first-page":"A\u2010105","article-title":"A randomized placebo\u2010controlled trial of infliximab therapy for active ulcerative colitis: Act I trial","volume":"128","author":"Rutgeerts P","year":"2005","journal-title":"Gastroenterology"},{"key":"e_1_2_4_60_2","first-page":"A\u2010104","article-title":"Infliximab induction and maintenance therapy for ulcerative colitis: the Act 2 trial","volume":"128","author":"Sandborn WJ","year":"2005","journal-title":"Gastroenterology"},{"key":"e_1_2_4_61_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.03.003"},{"key":"e_1_2_4_62_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01739.x"},{"key":"e_1_2_4_63_2","first-page":"A\u201026","article-title":"Infliximab for the treatment of pyoderma gangrenosum: a randomised, double\u2010blind placebo\u2010controlled trial","volume":"128","author":"Brooklyn T","year":"2005","journal-title":"Gastroenterology"},{"key":"e_1_2_4_64_2","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.135.5.564"},{"key":"e_1_2_4_65_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1997.01100150063010"},{"key":"e_1_2_4_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(03)00406-8"},{"key":"e_1_2_4_67_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(02)01292-7"},{"key":"e_1_2_4_68_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03239-6"},{"key":"e_1_2_4_69_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.511"},{"key":"e_1_2_4_70_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08215-6"},{"key":"e_1_2_4_71_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012664"},{"key":"e_1_2_4_72_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-3565(04)00238-1"},{"key":"e_1_2_4_73_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020888"},{"key":"e_1_2_4_74_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2003.50145"},{"key":"e_1_2_4_75_2","first-page":"A\u201054","article-title":"The effectiveness of immunosuppression to suppress the formation of antibodies to infliximab in Crohn's disease","volume":"126","author":"Noman M","year":"2004","journal-title":"Gastroenterology"},{"key":"e_1_2_4_76_2","first-page":"A26","article-title":"The clinical outcome of maintenance therapy with infliximab for luminal Crohn's disease is not affected by concomitant immunosuppressives: results of a multicenter randomized infliximab maintenance\/immunosuppressives discontinuation (imid) trial","volume":"128","author":"Van Assche G","year":"2005","journal-title":"Gastroenterology"},{"key":"e_1_2_4_77_2","first-page":"A44","article-title":"Infliximab in steroid dependent Crohn's disease patients treated with azathioprine or 6\u2010MP a randomized double\u2010blind placebo\u2010controlled trial","volume":"52","author":"Lemann M","year":"2003","journal-title":"Gut"},{"key":"e_1_2_4_78_2","first-page":"A577","article-title":"A randomized controlled trial evaluating the ideal medical management for Crohn's disease (CD): top\u2010down versus step\u2010up strategies","volume":"128","author":"Hommes D","year":"2005","journal-title":"Gastroenterology"},{"key":"e_1_2_4_79_2","first-page":"151","article-title":"Infliximab decreases resource use among patients with Crohn's disease","volume":"35","author":"Rubenstein JH","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_4_80_2","first-page":"A45","article-title":"Infliximab use in Crohn's disease: impact on health care resources","volume":"52","author":"Jewell DP","year":"2003","journal-title":"Gut"},{"key":"e_1_2_4_81_2","first-page":"A54","article-title":"Estimating cost\u2010effectiveness of maintenance infliximab for chronic active Crohn's disease from accent 1","volume":"52","author":"Wong JB","year":"2003","journal-title":"Gut"},{"key":"e_1_2_4_82_2","volume-title":"Periodic Safety Update Report (PSUR) Infliximab","year":"2005"},{"key":"e_1_2_4_83_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2003.10.047"},{"key":"e_1_2_4_84_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2004.01904.x"},{"key":"e_1_2_4_85_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2004.04148.x"},{"key":"e_1_2_4_86_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(03)00701-7"},{"key":"e_1_2_4_87_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20311"},{"key":"e_1_2_4_88_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00063-003-1282-9"},{"key":"e_1_2_4_89_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2003.018515"},{"key":"e_1_2_4_90_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2004.30186.x"},{"key":"e_1_2_4_91_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2005.02405.x"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2006.02786.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2006.02786.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T18:00:23Z","timestamp":1697392823000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2006.02786.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1,20]]},"references-count":90,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,2]]}},"alternative-id":["10.1111\/j.1365-2036.2006.02786.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2006.02786.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,1,20]]}}}